BURST CME™ Activity 2: Oral SERD Monotherapy: Understanding the Evidence Base

Activity Overview

Next-generation oral selective estrogen receptor degraders (SERDs) and the first proteolysis-targeting chimera (PROTAC) estrogen receptor degrader have expanded the treatment landscape for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (MBC), particularly for patients whose disease harbors an ESR1 mutation after progression on endocrine therapy and a CDK4/6 inhibitor. Three agents are now FDA approved as monotherapy in this setting: elacestrant, imlunestrant, and vepdegestrant. In this activity, 2 experts review the pivotal clinical trial evidence supporting oral SERD monotherapy, including the phase 3 EMERALD, EMBER-3, and VERITAC-2 studies, with attention to the magnitude of benefit observed in the ESR1-mutant population and in the endocrine-sensitive subgroup of patients who received prior endocrine therapy plus a CDK4/6 inhibitor for at least 12 months. Faculty then examine how these trial findings translate into routine clinical practice, drawing on real-world evidence for elacestrant that demonstrates outcomes consistent with the randomized data across multiple subgroups. The discussion also addresses practical considerations for patient selection and for anticipating, monitoring, and managing the distinct adverse-effect profiles of these agents to support shared decision-making in the second-line setting and beyond.

Target Audience

This educational program is primarily directed toward a global audience of medical oncologists, advanced practice providers, nurses, and other health care professionals who are involved in the management of patients with advanced or metastatic breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess emerging clinical trial and real-world evidence to gain practical insights into the appropriate use of oral SERD-based strategies for patients with HR+/HER2– MBC
• Apply evidence-based approaches to anticipate, monitor, and manage adverse effects associated with targeted therapies for patients with HR+/HER2– MBC

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Additional Disclaimers

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.

This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.

In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.

Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.